This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bubley, G. J. Articles by Balk, S. P. Search for Related Content PubMed PubMed Citation Articles by Bubley, G. J. Articles by Balk, S. P.

Treatment of Androgen-Independent Prostate Cancer

Beth Israel Hospital and Harvard Medical School, Division of Hematology/Oncology, Boston, Massachusetts, USA

Correspondence: Glenn J. Bubley, M.D., or Steven P. Balk, M.D., Ph.D., Beth Israel Hospital and Harvard Medical School, Division of Hematology/Oncology, 330 Brookline Avenue, Boston, MA 02215, USA. Telephone: 617-667-5288; Fax: 617-667-3915.

Androgen-ablative therapy for metastatic prostate cancer is effective for 60%-80% of men, but its effects are always finite and the majority of men develop androgen-independent disease within two years. Although current therapies for androgen-independent disease have not been shown to impact on survival, recent clinical and laboratory insights offer hope for effective therapy. For instance, recent data indicate that androgen-independent disease may still be dependent on hormonal stimulation, suggesting that hormonally based therapies may provide continued benefit. Chemotherapy, especially with estramustine and etoposide, seems to be an effective combination for a majority of patients. Treatment with suramin had been hampered by its side effects, but new dosing schedules are effectively circumventing toxicity. Radioisotopes such as strontium 89 have been shown to provide effective palliation for a majority of androgen-independent patients. Overall, these and other emerging efforts may be the foundation for therapies that offer hope for a significant survival benefit.

Key Words. Prostate cancer • Hormonal therapy • Androgen receptor • Chemotherapy

This article has been cited by other articles:

				S. R. Lee, S. M. Ramos, A. Ko, D. Masiello, K. D. Swanson, M. L. Lu, and S. P. Balk AR and ER Interaction with a p21-Activated Kinase (PAK6) Mol. Endocrinol., January 1, 2002; 16(1): 85 - 99. [Abstract] [Full Text] [PDF]